AMRI announces multi-year research agreement with Navigen Pharmaceuticals

AMRI (NASDAQ:AMRI) announced today that it has initiated a research collaboration with Navigen Pharmaceuticals, Inc. focused on the development of new drug therapies.

“AMRI has a proven track record of success working with biotech companies such as Navigen”

Under the terms of the multi-year agreement, AMRI will provide fully integrated drug discovery services including assay development, screening, in vitro ADMET, computer-aided drug discovery (CADD) and medicinal chemistry.

"AMRI has a proven track record of success working with biotech companies such as Navigen," said Michael P. Trova, Ph.D., senior vice president, chemistry. "Our ability to execute integrated biology and chemistry services under the helm of an experienced project manager ensures best practices are applied to the delivery of high quality preclinical candidates with a strong intellectual property position to our customers. We look forward to the opportunity to work with Navigen to help advance their early drug discovery efforts."